Highest-materiality recent filing
Jaguar Health Q2 2026 revenue down 59% YoY; net loss widens to $12.7M
Total net revenue $1.225M vs $2.979M in Q2 2025 (-59%); product revenue down 60% to $1.18M.
New agreement with Alivus Life Sciences for manufacture of crofelemer for Mytesi and other products.
Jaguar Health completes conversion of Series O Preferred Stock; shares outstanding now 4.86M
On June 25, 2026, all outstanding Series O Preferred Stock and shares issuable upon Eligible Warrants converted into common stock at 3.209:1 ratio.
Jaguar Health converts Series O Preferred Stock to common at 3.209:1, pays $2.68 for fractions
Each share of Series O Preferred Stock converted into 3.209 common shares on June 25, 2026; fractional shares paid in cash at $2.68/share.
Jaguar Health explores strategic alternatives for crofelemer rare disease program
Board initiates process to explore strategic alternatives including M&A, partnerships, licensing; no guarantee of transaction.
Jaguar Health explores strategic alternatives; crofelemer NDA targeted for rare intestinal failure
Board initiated process to evaluate strategic alternatives including M&A, partnerships, and licensing to maximize shareholder value.
Royalty amendments: Uptown and Streeterville minimum monthly payment increased to $750k, effective Oct 1, 2026.
Jaguar Health secures up to $40M equity line and $2M preferred stock financing
ELOC agreement provides up to $40M of common stock purchases; floor price set at $1.10 per share.
John Micek III elected Class II director with 3,967,085 for, 240,944 withheld.
Jaguar Health issues 64,668 common shares for Series Q Preferred; annual meeting adjourned to June 8
Issued 31,958 and 32,710 common shares to Streeterville on May 26 and June 1, 2026, respectively, in exchange for 3.72 and 4.2 Series Q Preferred shares.
Jaguar Health regains Nasdaq Bid Price compliance; monitoring until May 2027
Formal notice from Nasdaq on May 26, 2026: Jaguar complies with Bid Price Rule (closing bid ≥$1/sh).
Issued 54,222 common shares to Streeterville in exchange for 7.96 shares of Series Q Preferred Stock.
Jaguar Health Q1 revenue up 816% to $20.3M on $19M license deal; net loss narrows to $7.0M
Total revenue $20.3M (816% YoY increase) driven by $19.1M license revenue from Woodward/Future Pak deal.
Jaguar Health exchanges $22.7M in royalty interests for Series Q Preferred Stock
Uptown Capital: $12.5M royalty reduction for 500 Series Q shares.
Jaguar Health gets Nasdaq extension to May 18 for bid-price compliance; delisting risk remains
Received Nasdaq Staff notice on May 1, 2026 for non-compliance with 500,000 publicly held shares requirement.
Post 1-for-35 reverse stock split on April 30, 2026, publicly held shares are ~401,226, below 500,000 minimum.
Jaguar Health cures Nasdaq publicly held shares deficiency via warrant exercises after reverse split
Received Nasdaq notice on May 1, 2026 for non-compliance with minimum 500,000 publicly held shares after 1-for-35 reverse split on April 30.
Jaguar Health granted Nasdaq extension to May 15, 2026; announces 1-for-35 reverse stock split
Nasdaq Panel grants extension until May 15, 2026 to demonstrate compliance with $1.00 minimum bid price rule.
Jaguar Health stockholders approve authorized share increase and two reverse stock split proposals
Authorized common stock increased from 298M to 500M shares; total authorized shares from 352M to 554M.
Jaguar Health regains Nasdaq equity compliance after $27M in capital events
Stockholders' deficit was $18.7M at Dec 31, 2025, below Nasdaq's $2.5M minimum.
Net revenue FY2025 $11.5M (-1.5% YoY); Q4 2025 net revenue $3.2M (+5% QoQ, -8% YoY).
Jaguar Health postpones royalty payments, extends notes, terminates 48,211 warrants
Royalty payment start postponed to July 1, 2026; Uptown amount reduced to $11,125,282.54, Streeterville to $12,428,782.20.
Jaguar Health receives Nasdaq delisting notice for bid price; plans to appeal
Nasdaq notice on March 5, 2026: bid price below $1.00 for 30 consecutive business days.
Jaguar Health files Series O Preferred Stock certificate for special dividend payable March 4
Filed Certificate of Designation for 1,557,000 shares of Series O Convertible Preferred Stock.
Jaguar Health declared a one-time special stock dividend of Series O Preferred Stock on February 18, 2026.
Jaguar Health issues ~11.8M pre-funded warrants to reduce $2.04M in royalties and preferred stock
Reduced $1.19M Iliad royalty and $0.85M Streeterville royalty by issuing 1.55M and 1.11M pre-funded warrants.
Exclusive license to Future Pak for Mytesi (HIV/AIDS diarrhea) and Canalevia-CA1 (chemotherapy-induced diarrhea in dogs) in U.S.
Jaguar Health issues $350K in 6% notes with warrants; corrects prior filing dates
Issued $350,000 aggregate principal amount of 6% unsecured promissory notes to two accredited investors.
Jaguar Health issues $350K in 6% notes and warrants for 350K shares at $1.00
Issued $350,000 aggregate principal amount of unsecured promissory notes to two accredited investors.
Jaguar Health closes $350K private placement of 6% notes and warrants for working capital
Issued $350K aggregate principal of 6% unsecured promissory notes to accredited investors on Jan 6, 2026.
Jaguar Health swaps 91 Series M Preferred shares for 440K common shares and 1.6M pre-funded warrants
On Dec 9, exchanged 75 Series M Preferred for 400K common shares and warrant for 1,304,545 shares at $0.001.
JAGX stockholders approve three proposals; crofelemer MVID trial shows up to 37% PS reduction
Stockholders approved proposal to issue shares upon exchange/redemption of Series N Preferred Stock (1,032,716 For, 73,065 Against).
Jaguar Health amends $36M royalty obligations, extends debt, exchanges preferred for common
Royalty Interest amendments set minimum monthly payment of $750,000 per $12M royalty from April 1, 2026.
Jaguar Health issues $10.81M secured note to Streeterville Capital; $8M held as collateral
Net proceeds of $10M after $800K OID and $10K transaction expenses; interest 8% p.a., maturity 36 months.
Jaguar Health issues 286,532 shares to reduce royalty interest by $600,000
Issued 286,532 common shares in exchange for $600,000 reduction in outstanding royalty interest balance.
Jaguar Health raises $1M via PIPE: 161,583 shares + 479,442 pre-funded warrants at $1.56/share
Issued 161,583 common shares and 479,442 pre-funded warrants to Brown Stone Capital at $1.56/share (warrant price $1.5599); total proceeds $1M.
Jaguar Health raises $2.38M via Series N Perpetual Preferred Stock PIPE
Issued ~951 Series N Preferred shares at $2,500 stated value each for aggregate proceeds of $2.38M.
Jaguar Health: Crofelemer cuts TPN needs in MVID/SBS; FDA outlines sNDA path for breast cancer
All 7 proposals approved at Aug 19 annual meeting; directors elected, stock plan amended, share issuances authorized.
Jaguar Health extends ATM manager Lucid's term to Dec 31, 2025
Sixth ATM Amendment extends Lucid Capital Markets' service as manager from June 30 to Dec 31, 2025.
Jaguar Health cuts royalty debt by $6.5M, issues Series M preferred to Iliad and Streeterville
Issued 170 shares of Series M Preferred to Iliad for $4.25M reduction in October 2020 royalty interest.
Company entered Exchange Agreements with certain investors to replace ~$2.57M of 6% convertible notes originally due June 30, 2025; new maturity January 30, 2026.
Jaguar Health raises ~$1.5M in registered direct offering with warrants
Issued 246,306 shares at $6.09/share; gross proceeds ~$1.5M.
Jaguar Health reduces royalty debt by $1.016M via equity exchanges; Q1 results released
Issued 60,000 shares to Iliad for $466,200 reduction in October 2020 royalty interest.
Jaguar Health posts investor presentation on website; no specific content disclosed in filing
Slide presentation made available on May 9, 2025 under Item 7.01.
Jaguar Health obtains waiver from noteholders to resume ATM stock sales
Investors holding majority of $3.4M convertible notes waived VRT restriction.
Jaguar Health issues 57,500 shares to reduce royalty interest by $632,500
On April 30, 2025, issued 57,500 shares to a royalty interest holder in exchange for $632,500 reduction in outstanding balance.
Crofelemer reduces TPN up to 27% in MVID and 12.5% in SBS-IF in proof-of-concept trial
Initial POC data shows novel liquid crofelemer reduced parenteral support in MVID and SBS-IF patients by up to 27% and 12.5% respectively.
Jaguar Health to discuss initial crofelemer POC results for MVID and SBS-IF on April 30 webcast
Data presented April 26 at ELITE PED-GI Congress by Dr. Mohamad Miqdady.
Jaguar Health extends note maturity to July 2025, reduces royalty balance by $1.09M via stock
Issued 1,290,000 shares to a royalty holder in exchange for $1,094,952 reduction in outstanding royalty balance.
Jaguar Health files updated investor presentation for Ped-GI congress; no detailed data
CEO references updated investor presentation at 11th Annual Elite Ped-GI Congress 2025 in Abu Dhabi.
Mr. Greg J. Divis notified the Board of Directors (the “Board”) of Jaguar Health, Inc. (the “Company”) of his intention to resign as a member of the Board, effective as of July 1, 2022.
the Board, by resolution as contemplated in the Company’s bylaws, appointed Dr. Anula Jayasuriya to fill the vacancy created by Mr. Divis’s resignation and serve as Class III director of the Company
Max materiality 0.85 · Median 0.62 · Most common event other_material